Report
Valens Research

ISRG - Embedded Expectations Analysis - 2021 11 16

Intuitive Surgical, Inc. (ISRG) currently trades above corporate and historical averages relative to Uniform earnings, with a 64.1x Uniform P/E (Fwd. V/E').

At these levels, markets are pricing in expectations for Uniform ROA to reach new peaks of 87%, accompanied by 9% Uniform asset growth.

Meanwhile, analysts expect Uniform ROA to only slightly recover to 32% in 2022, accompanied by 12% Uniform asset growth.

If sustained going forward, these levels would imply a stock price closer to $156, representing significant potential equity downside for the firm.

Moreover, the firm's most recent earnings call suggests management may have concerns about supply chain issues, procedure revenue, product innovation, and Asia growth.
Underlying
Intuitive Surgical Inc.

Intuitive Surgical develops, manufactures, and markets the da Vinci? Surgical System and the Ion? endoluminal system. The systems consist of a surgeon console or consoles, a patient-side cart, a vision system, and proprietary instruments and accessories. The company's technology is designed to provide surgeons with a range of motion analogous to the motions of a human wrist, while filtering out the tremors inherent in a surgeon's hands. The company's primary platform for robotic-assisted surgery is its family of da Vinci Surgical Systems. The da Vinci Surgical System allows surgeons to operate while seated at an ergonomic console viewing a three-dimensional image of the surgical field.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch